Avalere Study Shows Medicare Part D Helping People... -
[Cached Version]
Published on: 3/12/2008
Last Visited: 11/5/2008
"Part D is meeting its goals of increasing access to, and affordability of, drugs to Medicare beneficiaries," said Valerie Barton, vice president of Avalere Health and co-author of the study.
...
"Knowing when people with diabetes may hit the coverage gap is important for physicians who can look for signs of non-compliance, and for individuals who can use this data for financial planning purposes," said Barton.
"The lack of change in the number of prescription drugs used invites more research on whether patients with type 2 diabetes tend to enroll in Part D plans that offered gap coverage, the financial sensitivity of patients with chronic illness, and generic switching patterns for patients in the coverage gap."
The Avalere study did not evaluate if Medicare drug coverage has translated into improved health for seniors with Medicare drug coverage.
According to Barton, this type of research is currently not feasible.
"Regrettably, outcomes research on the Medicare population post-Part D implementation is hindered by the lack of integrated data from Medicare Part A, B, and D. Policymakers should consider the value of this type of integrated medical and pharmacy claims dataset and work fast to make it available to enable a deeper evaluation of Part D's success or shortcomings."
Avalere used its proprietary DataFrame database of Part D plan benefit and formulary designs to characterize access to diabetes-related drugs in Part D and Wolters Kluwer's Source Lx, a nationally representative claims data repository, to analyze drug utilization and out-of-pocket costs from January 1, 2004 through September 30, 2007.
"The Impact of Medicare Part D on Beneficiaries with Type 2 Diabetes: Drug Utilization and Out-of-Pocket Expenses," was authored by Zeynal Karaca, Sonya B. Streeter, Valerie Barton, Khoa Nguyen, and Kris Norris, all of Avalere Health.